Stock Track | CARsgen-B Soars 5.91% Intraday on Pipeline Catalyst with Universal CAR-T Therapy Data Acceptance at EHA

Stock Track

May 07

CARsgen-B's stock surged 5.91% during intraday trading on Thursday, driven by positive pipeline developments.

The company announced that research abstracts for two of its universal CAR-T cell therapies, CT0596 and CT1190B, have been accepted for poster presentation at the upcoming European Hematology Association annual meeting. CT0596 targets BCMA for relapsed/refractory multiple myeloma and plasma cell leukemia, while CT1190B targets CD19/CD20 for relapsed/refractory B-cell non-Hodgkin lymphoma. This acceptance signifies a key pipeline advancement, with the company planning to initiate Phase Ib clinical trials for both candidates.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1183284959"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183284959\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183284959?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 10:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183284959","market":"us","top_or_hot":-1,"title":"Stock Track | CARsgen-B Soars 5.91% Intraday on Pipeline Catalyst with Universal CAR-T Therapy Data Acceptance at EHA","media":"Stock Track","content":"<p>CARsgen-B's stock surged 5.91% during intraday trading on Thursday, driven by positive pipeline developments.</p><p>The company announced that research abstracts for two of its universal CAR-T cell therapies, CT0596 and CT1190B, have been accepted for poster presentation at the upcoming European Hematology Association annual meeting. CT0596 targets BCMA for relapsed/refractory multiple myeloma and plasma cell leukemia, while CT1190B targets CD19/CD20 for relapsed/refractory B-cell non-Hodgkin lymphoma. This acceptance signifies a key pipeline advancement, with the company planning to initiate Phase Ib clinical trials for both candidates.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CARsgen-B Soars 5.91% Intraday on Pipeline Catalyst with Universal CAR-T Therapy Data Acceptance at EHA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CARsgen-B Soars 5.91% Intraday on Pipeline Catalyst with Universal CAR-T Therapy Data Acceptance at EHA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 10:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARsgen-B's stock surged 5.91% during intraday trading on Thursday, driven by positive pipeline developments.</p><p>The company announced that research abstracts for two of its universal CAR-T cell therapies, CT0596 and CT1190B, have been accepted for poster presentation at the upcoming European Hematology Association annual meeting. CT0596 targets BCMA for relapsed/refractory multiple myeloma and plasma cell leukemia, while CT1190B targets CD19/CD20 for relapsed/refractory B-cell non-Hodgkin lymphoma. This acceptance signifies a key pipeline advancement, with the company planning to initiate Phase Ib clinical trials for both candidates.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1183284959","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183284959","pubTimestamp":1778121304,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CARsgen-B's stock surged 5.91% during intraday trading on Thursday, driven by positive pipeline developments.The company announced that research abstracts for two of its universal CAR-T cell...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"个股追踪|EHA通用CAR-T疗法数据受理，科济源-B盘中大涨5.91%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARsgen-B's stock surged 5.91% during intraday trading on Thursday, driven by positive pipeline developments.The company announced that research abstracts for two of its universal CAR-T cell therapies, CT0596 and CT1190B, have been accepted for poster presentation at the upcoming European Hematology Association annual meeting. CT0596 targets BCMA for relapsed/refractory multiple myeloma and plasma cell leukemia, while CT1190B targets CD19/CD20 for relapsed/refractory B-cell non-Hodgkin lymphoma. This acceptance signifies a key pipeline advancement, with the company planning to initiate Phase Ib clinical trials for both candidates.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}